Clinical trial NCT05126186: Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure
Official title: Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure: a Phase II Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Hematologic Diseases
Graft Failure
Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2021-11-18
Enrollment: 35
Sex: ALL
Minimum age (years): 3
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Prognosis of patients with graft failure is dismal, and re-transplantation is the sole option for long-term survival. Currently, there is no consensus concerning therapeutic options in patients with primary or secondary (within the 60 days post-transplantation) graft failure and finding a new donor within an acceptable delay is challenging. Literature is poor on the subject while the overall survival of such patients is about 30% at 1 year. This situation thus represents today a very challenging unmet medical need.

Recently, haploidentical (haplo) related donor Stem Cell Transplantation (haplo-SCT) have improved dramatically outcomes using T-cell replete grafts with administration of post-transplantation cyclophosphamide (PTCy, which targets alloreactive T cells generated early after an HLA-mismatched transplant, sparing regulatory T cells and leaving unaffected the non-dividing hematopoietic stem cells) and standard post-transplant immune suppression with a calcineurin inhibitor (CNI) and mycophenolate mofetil. Our group re-transplanted a patient who experienced two consecutive graft failures and was successfully managed through a third haplo-SCT from her son using PTCy. We then retrospectively collected and analyzed data from 26 primary graft failure patients transplanted between 2011 and 2017 in 15 centers on behalf of French Society for Stem Cell Transplantation and Cell Therapy (SFGM-TC). The study population consisted mainly of patients with primary or secondary (within the 60 days post-transplantation) graft failure who underwent haplo-SCT and received PTCy as graft-versus-host-disease prophylaxis. The 1-year overall survival was about 60% suggesting that this approach might be a valid option in this particular poor clinical situation but now need validation through a phase II multicenter, national, prospective cohort study.


Eligibility criteria: Inclusion Criteria:

* Aged from 3 to 70 years
* All hematological diseases
* Suffering from primary or secondary (within the 60 days post-transplantation) graft failure after a 1st allo-SCT
* With usual criteria for allo-SCT:

  * ECOG ≤ 2
  * No severe and uncontrolled infection
  * Cardiac function compatible with high dose of cyclophosphamide
  * Adequate organ function: ASAT and ALAT ≤ 2.5N, total bilirubin ≤ 2N, creatinine clearance ≥30ml / min
* With identification of a haploidentical donor (brother, sister, parents, adult children or cousin)
* Absence of donor specific antibody (DSA) detected in the patient with a MFI ≥ 1500 (antibodies directed towards the distinct haplotype between donor and recipient)
* With health insurance coverage (bénéficiaire ou ayant droit).
* Understand informed consent or optimal treatment and follow-up.
* Contraception methods must be prescribed during all the duration of the research. Women and men of childbearing age must use contraceptive methods within 12 months and 6 months after the last dose of cyclophosphamide, respectively.
* Having signed a written informed consent (2 parents for patients aged less than 18)

Exclusion Criteria:

* Aged\< 3 years old and \>70 years old
* With uncontrolled infection
* With Seropositivity for HIV or HTLV-1 or active hepatitis B or C defined by a positive PCR HBV or HCV and associated hepatic cytolysis
* Yellow fever vaccine within 2 months before transplantation
* Cancer in the last 5 years (except basal cell carcinoma of the skin or "in situ" carcinoma of the cervix)
* Uncontrolled coronary insufficiency, recent myocardial infarction \<6 month, current manifestations of heart failure, uncontrolled cardiac rhythm disorders, ventricular ejection fraction \<50%
* Heart failure according to NYHA (II or more)
* Preexisting acute hemorrhagic cystitis
* Renal failure with creatinine clearance \< 30ml / min
* Urinary tract obstruction
* Pregnant (β-HCG positive) or breast-feeding
* Who have any debilitating medical or psychiatric illness, which preclude understanding the inform consent as well as optimal treatment and follow-up
* COVID vaccination or recent COVID disease \<3 months
* Tutorship or curatorship
* Contraindications to treatments used during the research

Primary outcomes:
measure: Overall Survival
timeFrame: at one year
Secondary outcomes:
measure: Graft failure incidence
timeFrame: at 3 months
measure: Neutrophils engraftment
timeFrame: at day 100
measure: Platelets engraftment
timeFrame: at day 100
measure: Absolute numbers of neutrophils
timeFrame: at 1 month
measure: Absolute numbers of neutrophils
timeFrame: at 2 months
measure: Absolute numbers of neutrophils
timeFrame: at 3 months
measure: Absolute numbers of neutrophils
timeFrame: at 6 months
measure: Absolute numbers of neutrophils
timeFrame: at 12 months
measure: Absolute numbers of neutrophils
timeFrame: through study completion, an average of 6 months
measure: Absolute number of platelets
timeFrame: at one month
measure: Absolute number of platelets
timeFrame: at 2 months
measure: Absolute number of platelets
timeFrame: at 3 months
measure: Absolute number of platelets
timeFrame: at 6 months
measure: Absolute number of platelets
timeFrame: at 12 months
measure: Absolute number of platelets
timeFrame: through study completion, an average of 6 months
measure: Incidence of use of growth factors for poor hematopoietic reconstitution
timeFrame: at 3 months
measure: Acute GvHD incidence
timeFrame: at 3 months
measure: Chronic GvHD incidence
timeFrame: at 24 months
measure: Relapse incidence
timeFrame: at 12 months
measure: Relapse incidence
timeFrame: at 24 months
measure: Progression free survival
timeFrame: at 12 months
measure: Progression free survival
timeFrame: at 24 months
measure: Incidence of CMV infection
timeFrame: at 12 months
measure: Incidence of EBV infection
timeFrame: at 12 months
measure: Incidence of severe infections
timeFrame: at 3 months
measure: Incidence of severe infections
timeFrame: at 6 months
measure: Incidence of severe infections
timeFrame: at 12 months
measure: Incidence of severe infections
timeFrame: at 24 months
measure: Incidence of veino-occlusive disease (VOD)
timeFrame: at 3 months
measure: Severity of veino-occlusive disease (VOD)
timeFrame: at 3 months
measure: Non-relapse mortality
timeFrame: at 24 months
measure: Incidence of cardiac toxicities
timeFrame: at 12 months
measure: Overall survival
timeFrame: at 24 months
measure: Interval between first allo-SCT and rescue haplo-SCT
timeFrame: at 60 days
measure: Quality of life for adults
timeFrame: at 3 months
measure: Quality of life for adults
timeFrame: at 6 months
measure: Quality of life for adults
timeFrame: at 12 months
measure: Quality of life for adults
timeFrame: at 24 months
measure: Quality of life for minors
timeFrame: at 3 months
measure: Quality of life for minors
timeFrame: at 6 months
measure: Quality of life for minors
timeFrame: at 12 months
measure: Quality of life for minors
timeFrame: at 24 months
measure: Proportion of patients with a donor chimerism of 90% or more
timeFrame: at 1 month
measure: Proportion of patients with a donor chimerism of 90% or more
timeFrame: at 3 months
measure: Proportion of patients with a donor chimerism of 90% or more
timeFrame: at 6 months
measure: Proportion of patients with a donor chimerism of 90% or more
timeFrame: at 12 months
measure: Immune reconstitution
timeFrame: at 3 months post-transplantation
measure: Immune reconstitution
timeFrame: at 6 months post-transplantation
measure: Immune reconstitution
timeFrame: at 12 months post-transplantation
measure: Immune reconstitution
timeFrame: at 24 months post-transplantation
measure: Iron overload estimation
timeFrame: at 3 months
measure: Iron overload estimation
timeFrame: at 6 months
measure: Iron overload estimation
timeFrame: at 12 months
measure: Iron overload estimation
timeFrame: at 24 months
Other outcomes:
Locations:
Study officials:
References: